GlassScriptPhysician profile
Xuan Kang
NPI 1144614173
$4,845.64
in general payments reported to CMS, 2019-2025
28 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $199 · 2021: $560 · 2022: $793 · 2023: $1,028 · 2024: $1,028 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,424.23 | 2022-2025 | |
| Argenx US, INC. | $507.88 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceuticals, INC. | $370.53 | 2020-2021 | |
| Allergan, INC. | $323.69 | 2020-2022 | |
| Pfizer INC. | $303.03 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $264.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $240.84 | 2021-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $197.28 | 2021-2024 | Emgality, Amyvid, Reyvow |
| Tanabe Pharma America, INC. | $137.09 | 2021-2023 | |
| Merz Pharmaceuticals, LLC | $115.89 | 2023-2025 | Xeomin, Inbrija |
| Scilex Pharmaceuticals INC. | $111.01 | 2023-2024 | Ztlido |
| Genentech USA, INC. | $108.09 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $107.33 | 2024 | Nayzilam, Rystiggo |
| Jazz Pharmaceuticals INC. | $100.81 | 2022-2024 | |
| Harmony Biosciences LLC | $81.33 | 2023-2025 | Wakix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $73.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $65.63 | 2023-2025 | |
| Axsome Therapeutics, INC. | $42.01 | 2025 | Symbravo, Sunosi |
| Impel Pharmaceuticals INC. | $41.67 | 2023 | Trudhesa |
| Avadel Cns Pharmaceuticals, LLC | $39.64 | 2024 | Lumryz |
| Catalyst Pharmaceuticals, INC. | $36.09 | 2025 | |
| Bioventus LLC | $31.05 | 2022-2023 | Gelsyn-3 |
| Averitas Pharma INC. | $27.02 | 2025 | Qutenza |
| Kedrion Biopharma INC. | $24.20 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $20.02 | 2025 | |
| Biogen, INC. | $18.34 | 2024 | Skyclarys |
| Janssen Scientific Affairs, LLC | $16.53 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.20 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xuan Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.